| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | SELL | SELL | SELL | SELL |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 1.27▼ | 1.27▼ | 1.27▼ | 1.28▼ | 1.28▼ |
| MA10 | 1.28▼ | 1.28▼ | 1.29▼ | 1.30▼ | 1.52▼ |
| MA20 | 1.29▼ | 1.29▼ | 1.29▼ | 1.27▼ | 1.77▼ |
| MA50 | 1.30▼ | 1.30▼ | 1.28▼ | 1.53▼ | 2.00▼ |
| MA100 | 1.29▼ | 1.26▼ | 1.28▼ | 1.84▼ | 2.53▼ |
| MA200 | 1.27▼ | 1.39▼ | 1.52▼ | 2.09▼ | 2.30▼ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.005▼ | -0.007▼ | -0.009▼ | 0.020▲ | -0.069▼ |
| RSI | 35.127▼ | 36.226▼ | 38.896▼ | 39.232▼ | 36.305▼ |
| STOCH | 34.848 | 21.795 | 21.795 | 51.594 | 17.962▼ |
| WILL %R | -100.000▼ | -100.000▼ | -100.000▼ | -47.794 | -82.031▼ |
| CCI | -147.156▼ | -145.540▼ | -145.443▼ | -47.267 | -83.859 |
|
Thursday, December 25, 2025 04:00 PM
While Celularity’s Biovance® and Biovance 3L products remained eligible for Medicare coverage under the now-withdrawn LCDs, Celularity CEO Dr. Robert J. Hariri welcomed the recent action taken under ...
|
|
Sunday, December 21, 2025 04:00 PM
FLORHAM PARK, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Celularity Inc. (Nasdaq: CELU) (“Celularity”), a regenerative and cellular medicine company addressing age-related and degenerative diseases, ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 22/01/26 | 1.24 | 1.28 | 1.24 | 1.24 | 65,363 |
| 21/01/26 | 1.35 | 1.35 | 1.25 | 1.25 | 6,552 |
| 20/01/26 | 1.34 | 1.37 | 1.2547 | 1.32 | 39,518 |
| 16/01/26 | 1.27 | 1.3495 | 1.27 | 1.31 | 27,519 |
| 15/01/26 | 1.30 | 1.338 | 1.25 | 1.29 | 49,081 |
| 14/01/26 | 1.37 | 1.37 | 1.30 | 1.33 | 5,915 |
| 13/01/26 | 1.33 | 1.37 | 1.25 | 1.35 | 66,580 |
| 12/01/26 | 1.31 | 1.32 | 1.2158 | 1.32 | 39,448 |
| 09/01/26 | 1.27 | 1.33 | 1.25 | 1.30 | 23,343 |
| 08/01/26 | 1.26 | 1.28 | 1.2304 | 1.26 | 33,705 |
|
|
||||
|
|
||||
|
|